News Intec Pharma Ltd TEL AVIV STOCK EXCHANGE

Equities

NTEC

IL0011177958

Delayed TEL AVIV STOCK EXCHANGE Other stock markets			5-day change	1st Jan Change
- ^ILa	-.--%		-0.67%	-16.62%

Mar. 14	Top Premarket Gainers	MT
Mar. 13	Indaptus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting	Apr. 11	AQ
Indaptus Therapeutics : April 2024 April 2024 Investor Presentation	Apr. 07	PU
Indaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor Conference	Mar. 28	AQ
Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting	Mar. 25	AQ
Indaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024	Mar. 18	AQ
Top Premarket Gainers	Mar. 14	MT
Indaptus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update	Mar. 13	AQ
Top Midday Gainers	Mar. 04	MT
Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort	Mar. 04	AQ
Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial	Mar. 04	CI
Indaptus Therapeutics to Present at the 2024 BIO CEO & Investor Conference	Feb. 15	AQ
Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels	Feb. 08	AQ
Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels	Feb. 08	CI
European Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform Technology	Jan. 04	AQ
Indaptus Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 06	CI
Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update	Nov. 06	AQ
Indaptus Therapeutics’ Decoy20 Demonstrated a Broad Immune Response of More than Fifty Cytokines and Chemokines in Patients Following a Single Dose in First Cohort of Ongoing Phase 1 Study	Nov. 06	AQ
Indaptus Therapeutics, Inc. Announces Interim Data from the First Cohort of Four Patients in the Phase 1 INDP-D101 Trial of Its Lead Compound, Decoy20	Nov. 06	CI
Indaptus Therapeutics, Inc. Releases Interim Data from the First Cohort of Four Patients in its Phase 1 INDP-D101 Trial of Its Lead Compound, Decoy20	23-10-31	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Intec Pharma Ltd TEL AVIV STOCK EXCHANGE

Equities

NTEC

IL0011177958

Summary

Filters